RxDoctor Payments Data

Burr Loew, MD

Gastroenterology · Concord, NHNPI 1245312073

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 39.3% of the total. Reporting peaked in 2023 at $562 and has fallen 72.1% since, to $157 in 2024.

$1,211in general payments, 2019–2025

Across 57 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$476
  • Bristol Myers Squibb$137
  • Takeda Pharmaceuticals U.S.A., Inc.$104
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
  • Pfizer$81
  • QOL Medical, LLC$54
  • plus $267 from 9 others

What the payments were for

  • Food & beverage$1,16997%
  • Education$423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,211 in reported general payments places this provider in the 60th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$115,090
Medicare patients
495
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab23$691,665
LinzessLinaclotide40$25,022
Mesalamine19$11,543
Ursodiol15$2,868
Dexlansoprazole DrDexlansoprazole17$2,363
Pantoprazole Sodium126$1,330
Omeprazole157$1,296
Lubiprostone13$1,173
Azathioprine21$1,113
Colestipol Hcl14$1,033
Esomeprazole Magnesium20$546
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$481
Dicyclomine Hcl40$398
Amitriptyline Hcl12$264
Lansoprazole14$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$53$691,66523 claims
AbbVieLinzess$476$25,02240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →